Comparing Brentuximab Vedotin–
Based Frontline Regimens for Hodgkin
Lymphoma in Older Patients
The combinations of brentuximab vedotin
(BV) and dacarbazine or BV and benda-
mustine both led to high objective response
rates (ORR) in older patients with previ-
ously untreated Hodgkin lymphoma (HL);
however, based on the frequency of serious
adverse events (AEs), the bendamustine-
containing regimen may be “too toxic” for
this patient population, according to results
of a phase II trial published in Blood.
ADVERSE REACTIONS
The following adverse reactions are discussed in greater detail
in other sections of the labeling:
• Hemorrhage [see Warnings and Precautions]
• Cardiotoxicity [see Warnings and Precautions]
• Hypersensitivity Reactions [see Warnings and Precautions]
• Copper Overload [see Warnings and Precautions]
• Tissue Necrosis [see Warnings and Precautions]
Adverse
Reaction
Musculoskeletal pain
Abdominal pain
Cough
Headache
Dyspnea
Fatigue
Arrhythmia
Decreased appetite
Pneumonia
(excluding fungal)
Sleep disorders
Bacteremia
(excluding sepsis)
Vomiting
Chills
Hypotension
Non-conduction
cardiotoxicity
Dizziness
Fungal infection
Hyperte